Related Experiment Video
Updated: Mar 24, 2026
Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian Cancer Organoids via Immunofluorescence Assays
Published on: February 24, 2023
Olaparib for the treatment of epithelial ovarian cancer
Jennifer McLachlan1, Susana Banerjee1
1a Gynaecology Unit , The Royal Marsden NHS Foundation Trust , London , UK.
Introduction:
Despite recent advances in the management of epithelial ovarian cancer, overall survival rates remain poor, and there is a pressing need to develop novel therapeutic agents and maintenance strategies to improve outcomes for women with this disease. Olaparib, a potent oral poly(ADP-ribose) polymerase (PARP) inhibitor, has demonstrated antitumor activity in women with ovarian cancer, associated with homologous recombination deficiency.
Areas Covered:
This review outlines the rationale for PARP inhibitor therapy in ovarian cancer and summarizes the efficacy and tolerability data for olaparib to date. Ongoing phase III clinical trials of olaparib in ovarian cancer will be discussed.
Expert Opinion:
There are a number of issues regarding the optimal use of olaparib in ovarian cancer, including the identification of a homologous recombination deficiency signature to predict treatment response, establishment of the optimal treatment setting (maintenance or relapsed disease), and evaluation of cost-effectiveness. Finally, the long term consequences of PARP inhibitors, including the risk of myelodysplasia and acute myeloid leukemia need to be quantified in ongoing large phase III clinical trials.
Insights
Olaparib, a PARP inhibitor, shows promise for ovarian cancer. Further research is needed to optimize its use and assess long-term safety, including risks of myelodysplasia and acute myeloid leukemia.
Area of Science:
- Oncology
- Pharmacology
Background:
- Epithelial ovarian cancer survival rates remain poor despite advances.
- Novel therapies and maintenance strategies are crucial for improving patient outcomes.
- Olaparib, a poly(ADP-ribose) polymerase (PARP) inhibitor, exhibits antitumor activity in ovarian cancer, particularly in cases with homologous recombination deficiency.
Purpose of the Study:
- To review the rationale behind PARP inhibitor therapy in ovarian cancer.
- To summarize the efficacy and tolerability data for olaparib.
- To discuss ongoing clinical trials investigating olaparib in ovarian cancer.
Main Methods:
- Literature review of PARP inhibitor therapy in ovarian cancer.
- Summary of olaparib efficacy and tolerability data.
- Discussion of ongoing Phase III clinical trials.
Main Results:
- Olaparib demonstrates antitumor activity in ovarian cancer patients.
- Efficacy and tolerability data for olaparib have been summarized.
- Ongoing Phase III trials will provide further insights.
Conclusions:
- Optimal use of olaparib requires identifying predictive biomarkers for treatment response (e.g., homologous recombination deficiency signature).
- Determining the ideal treatment setting (maintenance vs. relapsed disease) is essential.
- Long-term consequences, including risks of myelodysplasia and acute myeloid leukemia, require quantification in ongoing trials.
Related Concept Videos
02:56Treatment Resistent Cancers
02:56Treatment Resistant Cancers
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:57Targeted Cancer Therapies
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:49Cancer Therapies